Search clinical trials for: alterations in FGF or FGFR

Total 468285 results

Black Diamond Therapeutics, Inc.

Recruiting

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Non-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...

Korea, Republic of, United States
Zhujiang Hospital

Recruiting

EEG Alterations of Uterine Contractions in the First Stage of Labor Predicting Postpartum Depression

Postpartum Depression

China
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Intrahepatic Cholangiocarcinoma

Germany
National Cancer Institute (NCI)

Recruiting

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast Carcinoma

United States
Aadi Bioscience, Inc.

Recruiting

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Malignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic Neoplasm

Korea, Republic of, United States, Puerto Rico
The Fourth Affiliated Hospital of Zhejiang University...
Second Affiliated Hospital, School of Medicine, Zhejiang University

Recruiting

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
NYU Langone Health

Recruiting

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

Tympanic Membrane Perforation

United States
Hopital Foch
National Cancer Institute, France

Not yet recruiting

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM)

Glioblastoma, IDH-wildtype

France, Italy
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Advanced Liver Cancer

China
Hospices Civils de Lyon

Recruiting

FGF19 and Chronic Kidney Disease (RENAMUS 19)

Chronic Kidney Diseases

France
University of Florence
Azienda Ospedaliero-Universitaria Careggi; Istituto per lo Studio, la Prevenzione...

Recruiting

SLPI for Prostate Cancer

Prostate Cancer | Prostatic Neoplasm

Italy
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
The Affiliated Hospital of Qingdao University

Recruiting

Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)

Gastric or Gastro-oesophageal Junction Carcinoma | Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma | Second-line Therapy

China
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Medidata Solutions

Recruiting

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Centre Leon Berard
Centre de Recherche en Cancérologie de Lyon (CRCL)

Recruiting

Prospective Study of Immune Alterations in Operable Breast and Ovarian Carcinoma (GYNECO-IMM&CO)

Breast Carcinoma | Ovarian Carcinoma

France
University of Washington
Bayer

Recruiting

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Massachusetts Eye and Ear Infirmary

Recruiting

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Fuchs Endothelial Corneal Dystrophy

United States
Hopital Foch
AstraZeneca

Recruiting

Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients (ALU)

Bladder Cancer

France
Hutchmed

Recruiting

Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

China
Italo Biaggioni
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

Obesity-Associated Insulin Resistance

United States
University Health Network, Toronto
Bayer; AstraZeneca; Amgen; AnHeart Therapeutics Inc.; Applied Health Research Centre and other collaborators

Recruiting

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) (CARMA-BROS)

Cancer | Malignancies Multiple | Malignant Solid Tumor | Cancer, Therapy-Related | Molecular Sequence Variation | Genetic Alteration | Gene Fusion | Receptor Tyrosine Kinase Gene Mutation | RTK Family Gene Mutation | Ras (Kras or Nras) Gene Mutation

Canada
University of Roma La Sapienza

Recruiting

Impact of Adrenal IncidenTalomas and Possible Autonomous Cortisol Secretion on Cardiovascular and Metabolic Alterations (ITACA)

Adrenal Tumor | Adrenal Incidentaloma | Hypercortisolism

Italy
University Hospital, Bordeaux

Recruiting

Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. (GENEPI)

Rubinstein-Taybi Syndrome

France
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Centre Leon Berard

Recruiting

PATAKESS Protocol : Clinical and Biological Analysis of Exocrine Pancreatic Tumors (PATAKESS)

Exocrine Pancreatic Cancer

France
Shanghai Changzheng Hospital

Recruiting

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Advanced Solid Tumor

China
First Affiliated Hospital, Sun Yat-Sen University

Recruiting

Fibroblast Growth Factor 23 and Hypertensive Disorder Complicating Pregnancy

Hypertension, Pregnancy-Induced

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Infiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma

United States
University of Missouri-Columbia
Harry S. Truman Memorial Veterans' Hospital

Recruiting

Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Non Small Cell Lung Cancer | Hepatocellular Cancer

United States
University of Kansas Medical Center
Novartis Pharmaceuticals

Recruiting

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

End Stage Renal Disease

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Recruiting

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

Cancer

United States
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
Carmen Clapp
Universidad Autónoma de Querétaro; Instituto Mexicano de Oftalmologia (IMO); General... and other collaborators

Recruiting

Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema

Diabetic Retinopathy | Diabetic Macular Edema

Mexico
Institut Curie

Recruiting

Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE)

Cervical Cancer | Head and Neck Cancer | Ovarian Cancer | Triple-Negative Breast Cancer

France
Shinshu University

Recruiting

To Examine Whether or Not the Primary Causes of OA or RA Might be Bone Alterations

Osteoarthritis of Multiple Joints | Progression of Rheumatoid Arthritis

Japan
Centre Leon Berard
National Cancer Institute, France

Recruiting

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus)

Malignant Solid Neoplasms

France
National Cancer Institute (NCI)

Recruiting

Rapid Autopsy and Procurement of Cancer Tissue

Mesothelioma | Thymus Tumors | Adoptive Cellular Therapy | Genitourinary Cancers | Lung Cancers

United States
National Institute of Diabetes and Digestive and...

Completed

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Healthy Volunteers

United States
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
Daiichi Sankyo
AstraZeneca

Active, not recruiting

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Non-small Cell Lung Cancer

United States, Germany, Spain, Japan, Canada, France, Korea, Republic of, Italy, United Kingdom, China, Taiwan, Hungary, Singapore, Switzerland, Netherlands, Brazil, Mexico, Russian Federation, Puerto Rico, Poland, Hong Kong, Romania and more
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Prostate Carcinoma | Prostate Cancer Aggressiveness

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (CheckMate142)

Microsatellite Stable Colorectal Cancer | Mismatch Repair Proficient Colorectal Cancer | Microsatellite Unstable Colorectal Cancer | Mismatch Repair Deficient Colorectal Cancer

United States, Australia, Belgium, Canada, Ireland, Italy, Spain, France
Yonsei University

Completed

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel

Korea, Republic of
3D Medicines (Beijing) Co., Ltd.

Active, not recruiting

A Monotherapy in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

China, United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

X-Linked Hypophosphatemia

United States
Kyowa Kirin, Inc.

Completed

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Tumor Induced Osteomalacia (TIO) | Epidermal Nevus Syndrome (ENS)

United States

Search clinical trials for: alterations in FGF or FGFR

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations